Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 18/20 | 1.00 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.44 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.43 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9931538 | 0.87 | PTGES (1.00) | PTGESFFAR2ERCC1ERCC4 | |
| Ly-3031207 SCHEMBL9931208 | 0.85 | PTGES (1.00) | PTGES | |
| SCHEMBL9960827 | 0.84 | PTGES (0.73) | PTGESFFAR2 | |
| SCHEMBL9931625 | 0.83 | PTGES (0.71) | PTGES | |
| SCHEMBL9931255 | 0.83 | PTGES (1.00) | PTGESFFAR2 | |
| SCHEMBL9931813 | 0.82 | PTGES (1.00) | PTGES | |
| SCHEMBL9931545 | 0.82 | PTGES (1.00) | PTGESFFAR2 | |
| SCHEMBL9932157 | 0.82 | PTGES (0.81) | PTGES | |
| SCHEMBL9959252 | 0.81 | PTGES (0.67) | PTGESFFAR2 | |
| Hydrochloric Acid SCHEMBL9931386 | 0.80 | PTGES (0.66) | PTGESFFAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252831-B2 | Imidazole-2-benzamide compounds useful for the treatment of osteoarthritis | ELI LILLY AND COMPANY (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252831-B2 | Imidazole-2-benzamide compounds useful for the treatment of osteoarthritis | ELI LILLY AND COMPANY (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252831-B2 | Imidazole-2-benzamide compounds useful for the treatment of osteoarthritis | ELI LILLY AND COMPANY (US) | 2012-08-28 | — | — | US | disclosed |
| WO-2012087771-A1 | NOVEL IMIDAZOLE-2-BENZAMIDE COMPOUNDS USEFUL FOR THE TREATMENT OF OSTEOARTHRITIS | ELI LILLY AND COMPANY (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20120157506-A1 | Novel Imidazole-2-Benzamide Compounds Useful for the Treatment of Osteoarthritis | ELI LILLY AND COMPANY (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157506-A1 | Novel Imidazole-2-Benzamide Compounds Useful for the Treatment of Osteoarthritis | ELI LILLY AND COMPANY (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157506-A1 | Novel Imidazole-2-Benzamide Compounds Useful for the Treatment of Osteoarthritis | ELI LILLY AND COMPANY (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157506-A1 | Novel Imidazole-2-Benzamide Compounds Useful for the Treatment of Osteoarthritis | ARG2, HDAC6, COL2A1 | PTGES 550/4885FFAR2 1056/4885ERCC1 4812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.